Login to Your Account



Slowed Cognitive Decline May Be Path Forward

Lilly's Solanezumab Miss Is Another Setback in Alzheimer's

By Marie Powers
Staff Writer

Friday, August 24, 2012

Early Friday, Eli Lilly and Co. reported that Phase III Alzheimer's candidate solanezumab missed both the cognitive and functional endpoints in its two double-blind, placebo-controlled EXPEDITION trials in patients with mild-to-moderate disease.

The monoclonal antibody binds specifically to soluble amyloid beta and is aimed at drawing the peptide away from the brain through the blood.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription